Keyphrases
Malaria
100%
Plasmodium Falciparum
99%
Malaria Vaccine
50%
Merozoite
43%
Specific Antibodies
37%
Recombinant Protein
30%
Glutamate-rich Protein
27%
Lactococcus Lactis
27%
GMZ2
26%
Vaccine Candidate
26%
Blood Stage
26%
Antibody Response
25%
Trophozoite
24%
Exported Proteins
24%
Merozoite Surface Protein
23%
Stable Emulsion
22%
Tribal Population
21%
Longitudinal Cohort Study
21%
Vaccine Antigen
20%
Disulfide Bond
20%
Immunogenicity
20%
Ghanaian children
19%
Functional Antibodies
19%
Life Cycle Stages
18%
Confidence Interval
18%
Hazard Ratio
18%
IgG3
18%
TLR4 Agonist
17%
Recombinant Fusion
17%
CD4+ T
17%
Fusion Constructs
17%
Sexual Life
17%
Tricolor
17%
Clinical Malaria
17%
Eastern India
17%
Recombinant Products
17%
High Transmission
17%
MitoTracker
17%
Parasite Life Cycle
17%
Cytophilic
17%
Life Stages
17%
Transmission Zone
17%
Cell Response
17%
Clinical Development
17%
Risk Reduction
17%
Naturally Acquired Antibodies
17%
Antibody Targeting
17%
Humoral Response
17%
Phase 1 Trial
17%
Blood-stage Malaria
17%
Immunology and Microbiology
Plasmodium falciparum
95%
Antibody Response
46%
Merozoite
43%
Phagocytosis
41%
Antibody
39%
Trophozoite
34%
Lactococcus Lactis
26%
Immunogenicity
26%
Immunoglobulin G
23%
Rabies Vaccine
17%
Growth Inhibition
17%
Life Cycle Stage
17%
Adoptive Immunity
17%
Disulfide Bond
17%
Merozoite Surface Protein 2
17%
Respiratory Burst
17%
Protein Tertiary Structure
17%
Parasitemia
17%
TLR4
17%
Agonist
17%
T-Helper Cell
17%
Humoral Immunity
17%
Plasmodium
15%
